Dow Biomedica Co., Ltd. (CEO: Young-Gil Shin), a company specializing in in vitro diagnostic medical devices, announced that on February 5 it established a collaborative framework with Seoul Wirye Bio Long-Term Care Hospital to implement a long-term management model for cancer survivors. The model utilizes liquid biopsy–based precision testing to detect minimal residual disease (MRD) after treatment and monitor early signals of recurrence.

This collaboration leverages blood-based precision diagnostic technologies developed by Guardant Health, a global leader in liquid biopsy. Beyond managing patients with confirmed recurrence, the primary objective is to establish a structured longitudinal monitoring model in clinical practice that enables early detection of residual disease and proactive identification of recurrence signals following treatment.

Cancer survivors often continue to experience anxiety regarding potential relapse; however, comprehensive and precise follow-up care is not always maintained after discharge. To address this gap, the two institutions will apply advanced molecular diagnostic technologies to cancer survivors admitted to the long-term care hospital. Compared with conventional imaging modalities such as CT or MRI, these tests are designed to detect MRD or recurrence signals several months earlier. The technology is supported by extensive global clinical data and has already undergone technical validation at major medical institutions in Korea.

Rather than implementing the test as a one-time event, both parties aim to establish a continuous care pathway encompassing patient education, counseling, testing, and long-term follow-up management. Seoul Wirye Bio Long-Term Care Hospital will oversee on-site clinical implementation and patient communication, while Dow Biomedica will provide operational support to ensure stable test utilization, along with educational assistance for healthcare professionals and counseling staff.

A representative of Dow Biomedica stated, “This collaboration is meaningful in that it creates a sustained management pathway that extends beyond active treatment, helping to alleviate recurrence-related anxiety among cancer survivors. Moving forward, we plan to enhance patient accessibility based on real-world experience in long-term care settings and gradually expand the scope of collaboration.”